Mad Money w/ Jim Cramer Mad Money w/ Jim Cramer 1/14/26
Jan 15, 2026
Dr. Vlad Schorch, a biotech executive and CEO of Biohaven, discusses groundbreaking advancements in neuroscience and immunology. He shares insights into the company's endeavors in tackling obesity and epilepsy through innovative treatments. The conversation highlights recent clinical developments and financial strategies that showcase Biohaven's resilience in a competitive landscape. Jim Cramer and Dr. Schorch dive into the future potential of precision medicine, making complex topics engaging and accessible.
AI Snips
Chapters
Books
Transcript
Episode notes
Defensive Stocks Leading Signals Caution
- The market's current leadership is shifting toward defensive consumer staples and energy, which signals fear of economic slowdown.
- Jim Cramer warns that this leadership mix is unhealthy because it usually reflects recession expectations and inflationary pressure from oil.
Hedge Against Credit-Card Policy Risk
- Avoid overexposure to banks and discretionary names if politicians push to cap credit card rates.
- Hedge with consumer staples and healthcare names while the policy risk persists.
Bank Sell-Off Reflects Expectations Not Earnings
- Big national banks reported generally strong results but stocks fell due to cautious commentary and lofty prior gains.
- Cramer says the sell-off is mostly a breather and a 'guilt by association' reaction, not necessarily fundamental weakness.
